Alzamend Neuro, Inc. (ALZN) - Dilution Analysis

10-Q filing | 3.8M shares outstanding

8-K filing: Alzamend Neuro, Inc. issued 361,743 shares of common stock upon conversion of Series B Convertible Preferred Stock between October 1, 2025 and October 8, 2025.

10-K filing | 2.9M shares outstanding

8-K filing: Stock split 1-for-9 | Outstanding: 6,608,591 → 800,954

S-1/A filing: This prospectus relates to the resale of up to 75,775,110 shares of common stock of Alzamend Neuro, Inc. by Orchid Finance LLC.

S-3 filing: This prospectus relates to the resale of up to 75,775,110 shares of common stock of Alzamend Neuro, Inc. by Orchid Finance LLC, including shares to be issued upon conversion of preferred stock and exercise of a warrant.

10-Q filing | 6.6M shares outstanding

8-K filing: Alzamend Neuro, Inc. amended its bylaws to decrease the quorum requirement for a stockholder meeting from a majority to 35% and filed a Certificate of Designations for Series C Convertible Preferred Stock related to a Securities Purchase & Exchange Agreement with a sophisticated investor.

8-K filing: Alzamend Neuro, Inc. entered into a Securities Purchase & Exchange Agreement with a sophisticated investor to exchange Series A Convertible Preferred Stock for Series C Convertible Preferred Stock and sell up to 500 shares of Series C Convertible Preferred Stock and warrants for up to $5,000,000.00 less a five percent discount. ($1.93M proceeds)

10-Q filing | 5.4M shares outstanding

10-Q filing | 3.9M shares outstanding

10-K filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 7,981,763 → 798,176

S-1/A filing: This prospectus relates to the resale of up to 125,000,000 shares of common stock by the Selling Stockholder, consisting of shares issuable upon conversion of preferred stock and shares issuable upon exercise of warrants.

S-1/A filing: This prospectus relates to the resale of up to 125,000,000 shares of common stock of Alzamend Neuro, Inc. by Orchid Finance LLC.

S-1 filing: This prospectus relates to the resale of up to 125,000,000 shares of common stock of Alzamend Neuro, Inc. by Orchid Finance LLC, including shares to be issued upon conversion of preferred stock and exercise of warrants.

8-K filing: Alzamend Neuro, Inc. entered into a Securities Purchase Agreement to sell up to 2,500 shares of Series A Convertible Preferred Stock and warrants to purchase common stock for up to $25,000,000 in several tranche closings, subject to certain conditions including stockholder approval. ($25.0M proceeds)

8-K filing: Alzamend Neuro, Inc. sold 100 shares of Series B convertible preferred stock and warrants to purchase 100,000 shares of common stock to Ault Lending, LLC for $100,000, as part of an agreement where Ault Lending may purchase up to $6 million of Series B Preferred Stock and warrants. ($0.2M proceeds)

8-K filing: Alzamend Neuro, Inc. sold 780 shares of Series B convertible preferred stock and warrants to purchase 780,000 shares of common stock to Ault Lending, LLC for $780,000, completing a portion of a potential $6 million offering. ($1.56M proceeds)

10-Q filing | 7.1M shares outstanding

8-K filing: Alzamend Neuro, Inc. entered into a Securities Purchase Agreement with Ault Lending, LLC, selling 1,220 shares of Series A convertible preferred stock and warrants to purchase 1,220,000 shares of Common Stock for $1.22 million. ($1.22M proceeds)

10-Q filing | 6.6M shares outstanding

8-K filing: Stock split one-for-fifteen | Outstanding: 98,440,124 → 6,466,655

10-Q filing | 98.4M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell, from time to time, any combination of common stock, preferred stock, warrants, rights or units having an aggregate initial offering price not exceeding $25,000,000.

10-K filing | 97.5M shares outstanding

10-Q filing | 98.3M shares outstanding

10-Q filing | 97.5M shares outstanding

10-Q filing | 97.5M shares outstanding

10-K filing | 89.1M shares outstanding

10-Q filing | 90.1M shares outstanding

10-Q filing | 88.9M shares outstanding

10-Q filing | 86.9M shares outstanding

10-K filing | 67.4M shares outstanding

S-1/A filing: This is an S-1/A filing for the initial public offering of common stock. We are offering 2,500,000 shares of our common stock, with an expected initial price of $5.00 per share.

S-1/A filing: Alzamend Neuro, Inc. is offering 2,500,000 shares of common stock in its initial public offering, with an expected initial public offering price of $5.00 per share, and Digital Power Lending, LLC may purchase up to $10.0 million of common stock in this offering at the same price.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with a proposed offering of 2,500,000 shares at an expected price of $5.00 per share.

S-1/A filing: This is the initial public offering of shares of common stock of Alzamend Neuro, Inc. We are offering 2,500,000 shares of our common stock at an expected price of $5.00 per share.

S-1 filing: This is an S-1 filing for an initial public offering of common stock to fund research and development of AL001 and AL002, as well as for working capital and general corporate purposes.